Dr. Karl Thomae Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Gmbh

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

Karl Thomae Gmbh

Boehringer Ingelheim Kg

Wolfgang Grell

Robert Sauter

Rudolf Hurnaus

Manfred Reiffen

Eckhard Rupprecht

Gerhart Griss

Armin Heckel

Rainer Walter

Norbert Redemann

Bernhard Eisele

Walter Kobinger

Ludwig Pichler

Gerhart Griss, Deceased

Nikolaus Kaubisch

Frank Himmelsbach

Michael Entzeroth

Matyas Leitold

Joachim Kahling

Jacobus C A Van Meel

Norbert Hauel

Wolfgang Eberlein

Wolfgang Wienen

Michael Mark

Gerald Juergen Roth

Uwe Joerg Ries

Richard Reichl

Berthold Narr

Walter Haarmann

Rainer Soyka

Walter Spevak

Joachim Mierau

Gunter Schingnitz

Jacques Van Meel

Andreas Bomhard

Ulrike Tontsch-Grunt

Jacobus C Van Meel

Klaus Binder

Helmut Wittneben

Rudolph Hurnaus

Rainer Zimmerman

Robert Haigh

Jacobus Ca Van Meel

Thomas Von Rueden

Eckhard Ruprecht

Eric Haaksma

The present invention relates to new substituted indolinones of general formulawherein The above compounds of general formula I wherein Rdenotes a hydrogen atom, a C-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein Rdoes not represent a hydrogen atom, a C-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.

Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs

Substituted indolinones with kinase inhibitory activity

Substituted indolinones of general formula

Antithrombotic phenylalkyl derivatives of the formula

Antithrombotic phenylalkyl derivatives

Phenylacetic acid benzylamides having the following general structure

Phenylacetic acid benzylamides

The present invention relates to substituted indolinones of general formula

Indolinones having kinase inhibitory activity

The present application relates to the uses of phenylacetic acid benzylamides and new (S)(+)-2-ethoxy-4-[N-[1-2-piperidino-phenyl)-3-methyl-1-butyl]-aminocarbon ylmethyl]-benzoic acid and the salts thereof, which have valuable pharmacological properties, namely an effect on the intermediate metabolism, but particularly the effect of lowering blood sugar.

The present invention relates to indolinones of general formula ##STR1## wherein R.sub.1 to R.sub.3 are defined in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Indolinones having kinase-inhibiting activity

Substituted thiazoles, oxazoles and 2-hydroxy morpholine compounds useful in the treatment of diabetes mellitus and obesity are described.

Substituted thiazoles and oxazoles and 2-hydroxy-morpholines

A phenylalkyl derivative of the formula ##STR1## wherein R.sub.a to R.sub.f, A and B are substituents and n is the number 0 or 1. These phenylalkyl derivatives possess angiotensin antagonist activity.

Phenylalkyl derivatives, with pharmaceutical activity

Compounds of formula ##STR1## where the substituents are as defined herein, are disclosed, which compounds are useful in the treatment of diabetes and obesity, among other uses.

Substituted thiazoles useful for treatment of diabetes

The present application relates to the uses of phenylacetic acid benzylamides and new (S)(+)-2-ethoxy-4-[N-[1-2-piperidino-phenyl)-3-methyl-1-butyl]-aminocarbon ylmethyl]benzoic acid and the salts thereof, which have valuable pharmacological properties, namely an effect on the intermediate metabolism, but particularly the effect of lowering blood sugar.

Phenylethanolamines, their use as pharmaceuticals and as performance

Substituted thiazoles and oxazoles and pharmaceutical compositions and

Phenylacetic acid benzylamides having the following general structure ##STR1## wherein the substituents are defined herein, are disclosed, which compounds are hypoglcemic agents.

Growing community of inventors

Biberach, Germany

Wolfgang Grell